$2.10
7.14% yesterday
Nasdaq, Sep 27, 09:33 pm CET
ISIN
US0345691036
Symbol
ANEB
Sector
Industry

Anebulo Pharmaceuticals Inc Stock price

$2.05
+0.02 0.99% 1M
-0.73 26.26% 6M
-0.37 15.29% YTD
-1.01 33.01% 1Y
-5.02 71.00% 3Y
-4.95 70.71% 5Y
-4.95 70.71% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.09 4.59%
ISIN
US0345691036
Symbol
ANEB
Sector
Industry

Key metrics

Market capitalization $50.83m
Enterprise Value $47.74m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 13.33
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.31m
Free Cash Flow (TTM) Free Cash Flow $-8.09m
Cash position $3.09m
EPS (TTM) EPS $-0.32
Short interest 0.34%
Show more

Is Anebulo Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Anebulo Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Anebulo Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Anebulo Pharmaceuticals Inc:

Buy
100%

Financial data from Anebulo Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.76 4.76
23% 23%
-
- Research and Development Expense 3.55 3.55
37% 37%
-
-8.31 -8.31
29% 29%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8.31 -8.31
29% 29%
-
Net Profit -8.20 -8.20
30% 30%
-

In millions USD.

Don't miss a Thing! We will send you all news about Anebulo Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Anebulo Pharmaceuticals Inc Stock News

Neutral
Business Wire
2 days ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates.
Neutral
Business Wire
2 months ago
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), has been awarded the first tranche of a two year cooperative grant of up to approximately $1.9 million from the National Institute on Drug Abuse (“NIDA”), p...
Neutral
Business Wire
5 months ago
BOSTON--(BUSINESS WIRE)--Galehead Development, LLC (“Galehead”) and Rivian Automotive, LLC (“Rivian”) have entered into an agreement to collaborate on the development of renewable energy resources tailored to Rivian's locational and environmental priorities. Galehead will develop solar projects with specific consideration for Rivian's “3C” Framework. The 3C Framework is a progressive procuremen...
More Anebulo Pharmaceuticals Inc News

Company Profile

Anebulo Pharmaceuticals, Inc. engages in the provision of pharmaceutical services. The firm product candidate is ANEB-001, a potent, small molecule cannabinoid receptor antagonist, designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was founded by Lawyer Joseph F on April 23, 2020 and is headquartered in Lakeway, TX.

Head office United States
CEO Richard Cunningham
Employees 3
Founded 2020
Website www.anebulo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today